Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor–Naive Advanced ALK-Positive Non–Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial

Published 2021 View Full Article

Authors

Keywords

Anaplastic lymphoma kinase, ALK tyrosine kinase inhibitor, Brigatinib, Crizotinib, Non–small cell lung cancer

Journal

Journal of Thoracic Oncology

Volume -, Issue -, Pages -

Publisher

Elsevier BV

Online

2021-09-16

DOI

10.1016/j.jtho.2021.07.035

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started